We’re thrilled to be attending the BioTech Connect vendor show at the University of Toronto on April 29th. Ranked as the top college in Canada, the University of Toronto is renowned for its research and innovation across multiple disciplines. Come meet our team and learn how Biocytogen's off-the-shelf animal models and preclinical services can accelerate your studies.
What is BioTech Connect?
BioTech Connect (BTC) is an event planning company for life science product exhibitions across Canada. Created by experienced scientists from academia and industry, their mission is to connect laboratory suppliers with researchers nationwide. These informative scientific trade shows are held at universities and hospital based research centers to promote the latest lab products and supplier service.
Event Overview
Date: April 29th, 2026
Venue: Donnelly Centre for Cellular and Biomolecular Research University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada
Event Schedule
For more information about the BTC vendor show, please visit their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Toronto, Canada!
